KLOXXADO® (naloxone HCl) Nasal Spray 8 mg Shelf-Life Extended from 24 months to 36 months
The FDA has recently announced the approval of the shelf-life extension of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg from 24 to 36 months from date of manufacture. KLOXXADO® packaging has been updated with 36-month dating, starting with product manufactured in March 2024.
KLOXXADO® – a high dose option – is a ready-to-use nasal naloxone approved for the emergency treatment of known or suspected opioid overdose, providing an important treatment option in addressing the overdose epidemic. Naloxone has long been recognized as an important, safe and effective treatment in the fight against opioid overdose.
About Naloxone
Naloxone hydrochloride is a medicine that rapidly reverses an opioid overdose. It can quickly restore normal breathing in someone experiencing an opioid overdose and should be given to any person who shows signs of an opioid overdose or when an opioid overdose is suspected.
KLOXXADO® is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients. KLOXXADO® is not a substitute for emergency medical care. KLOXXADO® is intended for immediate administration as emergency therapy in settings where opioids may be present.
This product has been approved for marketing in the United States by the US FDA. This product approval does not confer the right on Hikma, or any other party, to market this product outside the United States.
Please see the Full Prescribing Information and Medication Guide for KLOXXADO® for complete product details.
NOTE: This article was not written by a medical professional and is not intended to substitute for the guidance of a physician. These are not Emergent’s recommendations, but rather facts and data collected from various reliable medical sources. For a full list of resources and their attributing links, see below.